New hope for blood cancer patients with tough fungal infections

NCT ID NCT07559032

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the drug amphotericin B can treat serious fungal infections that break through in people with blood cancers who are already taking antifungal prevention. About 15 adults will receive the drug for 4-6 weeks and be closely monitored. The goal is to see how well the infection responds and if the drug is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder Invasive Fungal Infections systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••